The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Recent major advances in understanding the molecular basis of acute myeloid leukemia
(AML) provide a double-edged sword. Although defining the topology and key features of …

Refractoriness to induction chemotherapy and relapse after achievement of remission are
the main obstacles to cure in acute myeloid leukaemia (AML). After standard induction …

Acute myeloid leukaemia (AML) incidence is age dependent, rising markedly in patients
aged! 60 years. Ageing of the European population may therefore contribute to the reported …

Background Despite the molecular heterogeneity of standard-risk acute myeloid leukemia
(AML), treatment decisions are based on a limited number of molecular genetic markers and …

Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …

Purpose Patients with acute myeloid leukemia (AML) who are in morphologic complete
remission are typically considered separately from patients with active disease (ie,≥ 5 …

Background The transplantation of cells, tissues, and organs has been recognised by WHO
as an important medical task for its member states; however, information about how to best …

Postremission therapy in patients with acute myeloid leukemia (AML) may consist of
continuing chemotherapy or transplantation using either autologous or allogeneic stem …

Overview: Evidence suggest that even patients aged 70 or above benefit from specific AML
therapy. The fundamental decision in AML then becomes whether to recommend standard …